Hebrew University Team Teaches an Old Drug New Tricks
New Delivery for Antibiotics Arms Medicine in the Fight against Antibiotic Resistance and COVID-19
May 4, 2020, Jerusalem: Researchers at the Hebrew University of Jerusalem have developed an injectable antibiotic with a new mode of action, which could have a significant impact on the morbidity rate for pandemics such as COVID-19, Yissum, the technology transfer company of the Hebrew University announced today.
Mupirocin, a highly effective topical antibiotic was re-formulated by Hebrew University researchers to allow for intravenous delivery, and in doing so they have created new properties to fight drug-resistant bacteria. According to some studies, close to 50% of COVID-19 deaths involved secondary bacterial infections.
According to the European Antibiotic Resistance Organization (AMR), 700,000 people die every year from resistant infections, and if no significant improvement is made in the field, that number will rise to 10 million by 2050. For patients in hospitals with weakened immune systems, such as those with COVID-19, the danger is acute. Moreover, the intensive use in antibiotics during this pandemic is expected to increase this problem even further.
Antibiotic resistance is one of the leading threats to global health, according to the World Health Organization and the USCenters for Disease Control. Prof. Yechezkel Barenholz, the chief researcher behind the study, said, “The ability to take an existing drug and alter the way it works can have a significant impact on the problem of antibiotic resistance and secondary bacterial infections related to COVID-19 and may pave the way for a new treatment regimen. We have had very strong results from relevant animal models, and are looking forward to moving into clinical trials with Nano-mupirocin (the nano-liposomal formulation of mupirocin), as we believe the potential of this discovery is immense.” A toxicity study conducted with Nano-mupirocin demonstrated a very good safety profile enabling human trials.
The innovative treatment, which was advanced through the use of artificial intelligence (AI), was chiefly developed by Prof. Barenholz, who heads the Laboratory of Membrane and Liposome Research at Hadassah Medical School and Dr. Ahuva Cern in collaboration with Prof. Amiram Goldblum, all of whom hail from the Hebrew University Faculty of Medicine. The research received support from the National Institute of Health (NIH).
“Our study demonstrates how nano-liposomes have enabled the creation of a novel injectable antibiotic, and how we have overcome the limitations of existing antibiotics by using nano-technology approaches,” said Dr. Cern. “This drug, if approved, fundamentally enhances arsenal of antibiotics available to treat resistant infections, including those associated with COVID-19.”
The Hebrew University researchers developed the treatment as part of a groundbreaking study conducted with their German colleagues at the Helmholtz Centre for Infection Research (HZI).
Prof. Barenholz, a world-renowned expert in liposome based drug development also played a leading role in developing Doxil, a chemotherapy drug based on nano-delivery used to fight cancer through which was commercialized by Yissum, the tech transfer company of the Hebrew University.